Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2458-2469

  Oh, Ding Yuan ^a   Lowther, Sue ^b   McCaw, James M ^c,d   Sullivan, Sheena G ^a   Leang, Sook Kwan ^a   Haining, Jessica ^b   Arkinstall, Rachel ^b   Kelso, Anne ^a   Mcvernon, Jodie ^c,d   Barr, Ian G ^a,e   Middleton, Deborah ^b   Hurt, Aeron C ^a,e  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b CSIRO   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF BALLARAT   (Australia)

Author keywords

A(H1N1)pdm09; Antiviral; Neuraminidase inhibitors; Pandemic

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FERRET; INFECTION PREVENTION; INFLUENZA A (H1N1); MALE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRE EXPOSURE PROPHYLAXIS; PROPHYLAXIS; SECONDARY INFECTION; SEROLOGY; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DISEASE TRANSMISSION; HUMAN; INFLUENZA, HUMAN; PATHOLOGY; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES; SEVERITY OF ILLNESS INDEX; TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; FERRETS; HUMANS; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; PRE-EXPOSURE PROPHYLAXIS; SEVERITY OF ILLNESS INDEX; VIRAL LOAD; VIRUS SHEDDING;

EID: 84905971195     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku146     Document Type: Article

References (41)

1. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
2. Barr IG, Hurt AC, Deed N et al. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antiviral Res 2007; 75: 173-6.
3. ChinaBioToday. China's SFDA Ready to Fast-Track Approvals of Peramivir, a Flu Treatment. 2013. http://www.chinabiotoday.com/articles/20130408_1 (13 March 2014, date last accessed).
4. Chairat K, Tarning J, White NJ et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol 2013; 53: 119-39.
5. Hayden FG, Atmar RL, Schilling M et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43.
6. Peters PH Jr, Gravenstein S, Norwood P et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025-31.
7. Welliver R, Monto AS, Carewicz O et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748-54.
8. Hayden FG, Belshe R, Villanueva C et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189: 440-9.
9. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009; 361: e110.
10. Muthuri SG, Myles PR, Venkatesan S et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207: 553-63.
11. Pebody RG, Harris R, Kafatos G et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerg Infect Dis 2011; 17: 990-9.
12. Lee VJ, Yap J, Tay JK et al. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against influenza A H1N1 2009. BMC Infect Dis 2010; 10: 164.
13. Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; issue 1: CD008965.
14. McVernon J, McCaw JM, Nolan TM. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response. Aust N Z J Public Health 2010; 34: 113-9.
15. Homeland Security Council. National Strategy for Pandemic Influenza Implementation Plan. USA: Homeland Security Council, 2006.
16. Kim HM, Kang YM, Ku KB et al. The severe pathogenicity of alveolar macrophage-depleted ferrets infected with 2009 pandemic H1N1 influenza virus. Virology 2013; 444: 394-403.
17. Itoh Y, Shinya K, KisoM et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021-5.
18. Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325: 484-7.
19. Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325: 481-3.
20. Govorkova EA, Ilyushina NA, Boltz DA et al. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51: 1414-24.
21. Zhang Q, Shi J, Deng G et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013; 341: 410-4.
22. Dimmock NJ, Dove BK, Meng B et al. Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res 2012; 96: 376-85.
23. Oh DY, Barr IG, Mosse JA et al. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 2008; 46: 2189-94.
24. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938; 27: 493-7.
25. Rockman S, Brown LE, Barr IG et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 2013; 87: 3053-61.
26. Hurt AC, Okomo-Adhiambo M, Gubareva LV. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol Biol 2012; 865: 115-25.
27. Deng YM, Caldwell N, Hurt A et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 2011; 90: 87-91.
28. Sugaya N, Shinjoh M, Mitamura K et al. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect 2011; 63: 288-94.
29. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6.
30. Hayden FG. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther 2012; 17: 133-41.
31. Roberts KL, Shelton H, Stilwell P et al. Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. PLoS One 2012; 7: e43303.
32. Ward P, Small I, Smith J et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1: i5-21.
33. Mendel DB, Tai CY, Escarpe PA et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640-6.
34. Hurt AC, Lowther S, Middleton D et al. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res 2010; 87: 361-6.
35. van der Vries E, Stittelaar KJ, van Amerongen G et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog 2013; 9: e1003343.
36. Li W, Escarpe PA, Eisenberg EJ et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42: 647-53.
37. Govorkova EA, Marathe BM, Prevost A et al. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. Antiviral Res 2011; 91: 81-8.
38. Maines TR, Belser JA, Gustin KM et al. Local innate immune responses and influenza virus transmission and virulence in ferrets. J Infect Dis 2012; 205: 474-85.
39. Lauder SN, Jones E, Smart K et al. Interleukin-6 limits influenzainduced inflammation and protects against fatal lung pathology. Eur J Immunol 2013; 43: 2613-25.
40. Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-24.
41. Komiya N, Gu Y, Kamiya H et al. Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. J Infect 2010; 61: 284-8.